Petros Pharmaceuticals executed a general release and severance agreement with Mitchell Arnold effective June 18, 2026, providing two months base salary, 3,000 accelerated restricted shares, and tax assistance totaling approximately $11,206. The separation represents a routine workforce reduction with defined financial obligations and equity acceleration terms.